Worth reading
68In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Decision and Details
Post-merger disclosure relating to the absorption-type merger
Decision1 July 2026 (date of execution of the absorption-type merger agreement)
Implementation1 September 2026 (actual date of implementation and effective date)
Going forwardThe company plans to register the change under Article 921 of the Companies Act within 2 weeks of 1 September 2026
AmountMerger consideration: none; LINEヤフー assets: ¥3,782,588 million; LINEヤフー liabilities: ¥1,551,601 million; LINEヘルスケア assets: ¥356,793 thousand; LINEヘルスケア liabilities: ¥1,486,504 thousand; total year-end dividend: ¥50,215 million
Quantity / scaleShareholder of LINEヘルスケア: LINEヤフー only; stock acquisition rights: none issued
Reason
LINEヘルスケア was a wholly owned subsidiary of LINEヤフー, which held all of its issued shares. The two companies were under common control.
| Item | Details |
|---|---|
| Matter Covered | Post-merger disclosure relating to the absorption-type merger |
| Decision Date | 1 July 2026 (date of execution of the absorption-type merger agreement) |
| Implementation Date | 1 September 2026 (actual date of implementation and effective date) |
| Amount | Merger consideration: none; LINEヤフー assets: ¥3,782,588 million; LINEヤフー liabilities: ¥1,551,601 million; LINEヘルスケア assets: ¥356,793 thousand; LINEヘルスケア liabilities: ¥1,486,504 thousand; total year-end dividend: ¥50,215 million |
| Quantity / scale | Shareholder of LINEヘルスケア: LINEヤフー only; stock acquisition rights: none issued |
| Reason | LINEヘルスケア was a wholly owned subsidiary of LINEヤフー, which held all of its issued shares. The two companies were under common control. |
| Governing Rule | Article 801, paragraph 1 of the Companies Act; Article 200 of the Ordinance for Enforcement of the Companies Act; Articles 782, 784, 785, 787, 789, 796, 797, 799 and 921 of the Companies Act; Article 161, paragraph 2 of the Act on Book-Entry Transfer of Company Bonds, Shares, etc.; Article 2, paragraph 3, item 36 of the Ordinance on Company Accounting |
| Related previous disclosures | Disclosure documents issued before the merger dated 2 July 2026 |
| Future plans | The company plans to register the change under Article 921 of the Companies Act within 2 weeks of 1 September 2026 |
Items this document does not state (3)
Decision-Making BodyPeriod CoveredImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The filing states that LINEヘルスケア was a wholly owned subsidiary of LINEヤフー, that the two companies were under common control, and that the transaction qualified as a simplified absorption-type merger.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.